20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3062% below fair value

$0.20+0.00 (+0.25%)

Close on Nov 13, 2026Market cap $2.61MP/E –Yield –

20/20 Biolabs r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $592.57K, down 53.0% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$592.57K	-53.0%
FY2024	Dec 31, 2024	$1.26M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$257.63K	–
Q1 FY2026	Mar 31, 2026	$153.48K	–
Q2 FY2025	Jun 30, 2025	$194.12K	–
Q1 FY2025	Mar 31, 2025	$136.83K	–

Parsed from the XBRL in 20/20 Biolabs's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIDX.

Revenue growth16.7% · median -18.5%

Gross margin29.6% · median -10.2%

Operating margin-162.9% · median -695.7%

Net margin-182.8% · median -698.5%

Advertisement
300 × 250

See a number that looks wrong?